Eli lilly (lly) earnings Q4 2024

Eli Lilly reported Thursday Mixed results In the fourth quarter, even when demand for its blockbuster weight loss, drugs Zepbound and diabetes treatment Mounjaro increased.

The company’s quarterly earnings topped Wall Street estimates, but sales fell just short when Mounjaro saw lower realized prices. Zepbound and Mounjaro have now underpinned the expectations of two equal quarters, with the company previously pointing to questions about stock falling among wholesalers.

The pharmaceutical giant also issued accounting of 2025 surplus guidance of $ 22.05 to $ 23.55 per year. Stock, which is in line with what analysts expected. Eli Lilly repeated his 2025 fiscal sales guide of $ 58 billion to $ 61 billion.

The figures were in line with the preliminary results that Eli Lilly shared in January, which disappointed investors. Eli Lilly had cut his revenue guidance from 2024, as it said the demand for his weight loss and diabetes medicine would not meet its high expectations.

In particular, Eli Lilly said it is planning to report data on late phase about its next generation of obesity with drug medicine later in the year, a few months earlier than expected. Retatruid time works differently from any of the treatments on the market and mimics three different hungry hormones: GLP-1, Gip and Glucagon.

Here’s what Eli Lilly reported for the fourth quarter compared to what Wall Street expected, based on a study of analysts of LSEG:

• Earnings per Stock: $ 5.32 adjusted vs. $ 4.95 Expected
• Revenue: $ 13.53 billion against $ 13.57 billion expected

The company had a turnover of $ 4th of $ 13.53 billion, an increase of 45% from the same period a year ago.

The pharmaceutical giant booked a net income of $ 4.41 billion or $ 4.88 per year. Share for the fourth quarter. It is compared to a profit of $ 2.19 billion or $ 2.42 per year. Stock a year earlier.

Excluded disposable articles associated with the value of intangible assets and other adjustments, Eli Lilly issued a $ 5.32 earnings. Share for the fourth quarter of 2024.

Mounjaro sent $ 3.53 billion in revenue for the fourth quarter, an increase of 60% from the previous year. Analysts had expected the drug to book $ 3.62 billion in sales for the quarter, according to StreetAccount.

Eli Lilly said the increase reflects strong demand and increased supply of Mounjaro, but was partially offset by lower realized prices due to “favorable changes” in the fourth quarter of 2023 to estimates of discounts and discounts.

Meanwhile, the results Zepbound’s first full year in the US market. The weekly injection rocked at $ 1.91 billion in sales for the fourth quarter, which is below the $ 1.98 billion that analysts expected, according to StreetAccount.

But demand in the United States has still far surpassed supply to Eli Lilly’s Incretin substances, such as Zepbound and Mounjaro, in the last year. Both treatments mimic certain intestinal hormones to dampen a person’s appetite and regulate their blood sugar.

The popularity of these injectable drugs has forced both Eli Lilly and its rival Novo Nordisk to invest billions to increase production capacity for their treatments. The effort seems to pay off: Food and Drug Administration in December confirmed its decision to declare the US deficiency of Tirzepatide – the active ingredient in Zepbound and Mounjaro – over.